Ancient Garden's Wellness Center

10/06/2025

Archaeologists in southern Spain uncovered a 5,000-year-old dagger carved entirely from rock crystal, discovered within the Montelirio Tholos, a vast megalithic tomb.

Measuring 8.5 inches, this luminous blade was found beside arrowheads, blades, and a crystal core, forming a rare arsenal seemingly shaped from light itself. Known as The Shard of Eternity, legend holds that the dagger belonged to a revered chieftain, a leader who bridged the physical and spiritual realms.

In Neolithic belief, rock crystal symbolized purity and connection to the divine used not for battle, but for ceremony and transcendence. Its radiant surface, still gleaming after millennia, reflects humanity’s early fascination with death, spirit, and eternity.

More than a weapon, it was a symbol of power, faith, and the enduring mystery of the afterlife.

09/20/2025

09/20/2025

🙌🏾💚🌱

07/26/2025

🙌🏾🌱

In a bold and inspiring act of environmental activism, Brazilian skydiver Luigi Cani jumped from 6,500 feet to scatter 100 million seeds over deforested areas of the Amazon. His aerial seed planting initiative, which uses a high-tech system to replant native trees, demonstrates the power of creative solutions to heal our planet. When we take bold actions like this, we prove that even small seeds can grow into massive impacts. 🌳✈️

05/12/2025

🙌🏾🌱🌍😔

05/06/2025

Embrace your unique style with SLAYYY - ITCH-FREE, luxurious, pre-stretched & pre-feathered synthetic braiding hair, delivering stunning curls and a perfect fit for a Queen.

04/30/2025

04/29/2025

Scientists have created a powerful new chemotherapy drug, NUC-7738, by modifying Cordycepin — a natural compound found in a Himalayan fungus traditionally used in Chinese medicine.
Normally, Cordycepin breaks down quickly in the body, limiting its cancer-fighting potential. To solve this, biotech company NuCana applied ProTide technology, chemically enhancing Cordycepin to resist breakdown and pe*****te cancer cells more effectively, boosting its potency by up to 40 times.
Early lab experiments and Phase 1 clinical trials have delivered promising results with minimal side effects.
During Phase 2 trials, combining NUC-7738 with pembrolizumab helped control disease progression in 75% of patients who had run out of other treatment options.
Buoyed by these outcomes, NuCana plans to expand Phase 2 trials in 2025 and is in talks with the FDA about potential approval.

04/17/2025